Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Core Insights - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing high-purity pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections [1][2] - The company is advancing a broad pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus [2] Company Overview - Armata Pharmaceuticals utilizes proprietary bacteriophage-based technology for its therapeutic developments [2] - The company has in-house phage-specific cGMP manufacturing capabilities to support full commercialization of its products [2] Upcoming Events - Dr. Deborah Birx, the CEO of Armata, will present at the 7th Annual Bacteriophage Therapy Summit on March 13, 2025, in Boston, MA [1]